HLS Therapeutics Inc. Sustainability Profile
HLS Therapeutics Inc., a prominent player in the pharmaceutical industry, is headquartered in Canada and operates extensively across North America. Founded in 2017, the company has quickly established itself as a leader in the development and commercialisation of innovative therapies, particularly in the areas of cardiovascular and central nervous system disorders. HLS Therapeutics is renowned for its unique portfolio of products, including the well-regarded drug, Nabilone, which addresses chronic pain and nausea. The company’s commitment to enhancing patient outcomes through specialised treatments has positioned it favourably within the competitive landscape. With a focus on delivering high-quality, evidence-based solutions, HLS Therapeutics continues to achieve significant milestones, solidifying its reputation as a trusted name in healthcare.
DitchCarbon Score
How does HLS Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
HLS Therapeutics Inc.'s score of 28 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
HLS Therapeutics Inc.'s reported carbon emissions
HLS Therapeutics Inc., headquartered in Canada, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that HLS Therapeutics may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the company does not inherit emissions data from a parent organization, it operates independently regarding its climate impact reporting. Without specific emissions figures or reduction initiatives, HLS Therapeutics Inc. remains in a position where it could benefit from developing a comprehensive climate strategy to align with industry standards and expectations for sustainability.
How Carbon Intensive is HLS Therapeutics Inc.'s Industry?
How Carbon Intensive is HLS Therapeutics Inc.'s Location?
HLS Therapeutics Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
HLS Therapeutics Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
